• Home
  • NEW DAY MEDICINE
  • 9 (47) 2022
  • 5 — 9 (47) 2022 — Badridinova B.K., TREATMENT OF IRON-DEFICIENCY ANEMIA IN CHRONIC KIDNEY DISEASE AND END-STAGE RENAL INSUFFICIENCY

5 — 9 (47) 2022 — Badridinova B.K., TREATMENT OF IRON-DEFICIENCY ANEMIA IN CHRONIC KIDNEY DISEASE AND END-STAGE RENAL INSUFFICIENCY

TREATMENT OF IRON-DEFICIENCY ANEMIA IN CHRONIC KIDNEY DISEASE AND END-STAGE RENAL INSUFFICIENCY

Badridinova B.K., Bukhara State Medical Institute

Resume

Anemia is a common complication of chronic kidney disease (CKD) and is associated with reduced quality of life, increased morbidity and mortality. The mechanisms of development of anemia associated with CKD are varied and complex. These include, among others, reduced endogenous erythropoietin (EPO) production; absolute or functional iron deficiency, and inflammation with elevated hepcidin levels. Patients are most commonly prescribed oral or intravenous iron and erythropoiesis-stimulating drugs (EPO). However, these treatments are risky and sometimes not effective enough. However, significant advances have been made in recent years in the treatment of anemia associated with CKD, which have generated great promise. This article reviews current knowledge on the pathophysiology of anemia associated with CKD, current and future treatments, and trends in the management of patients with unmet target levels.

Keywords: anemia, chronic kidney disease, erythropoiesis stimulators, iron, hepcidin.

First page

24

Last page

30

For citation: Badridinova B.K., TREATMENT OF IRON-DEFICIENCY ANEMIA IN CHRONIC KIDNEY DISEASE AND END-STAGE RENAL INSUFFICIENCY //New Day in Medicine 9 (47)2022 24-30 https://l.clck.bar/74c71

LIST OF REFERENCES:

  1. Дедов И.И., Мельниченко Г.А., М. Алгоритмы оказания специализированной медицинской помощи больным сахарным диабетом, издание 4 дополненное, изд.: ООО «Информполиграф», 2019. – 104 с.
  2. Дедов И.И., Шестакова М.В. Сахарный диабет: руководство для врачей М., Universum Publishing, 2013. – 455 с.
  3. IDF Диабет Атлас 2021 – 10-е издание.
  4. Тахирова Ф., Алиханова Н. Сахарный диабет в Ташкентской области Узбекистана/Endocrine Abstracts (2022) 81 EP1189.
  5. Djuraeva Sh.A., Badridinova B.K.. “Methods for preventing the development of terminal renal failure in patients with type 2 diabetes mellitus.” // British Medical Journal 2.1 (2022).
  6. Kamalidinovna B.B. (2022). Features of Phosphoric-Calcium Exchange in Patients Treated with Program Hemodialysis. Research Journal of Trauma and Disability Studies, 1(2), 39–45. Retrieved from http://journals.academiczone.net/index.php/rjtds/article/view/60
  7. Minutolo R., Conte G., Cianciaruso B., Bellizzi V., Camocardi A., De Paola L DNL. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. // Nephrol Dial Transplant. (2012) 27:2880–6. 10.1093/ndt/gfs007
  8. Inker L.A., Grams M.E., Levey A.S., Coresh J., Cirillo M., Collins J.F., et al. Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data meta- analysis in a global consortium. // Am J Kidney Dis. (2019) 73:206–17. 10.1053/j.ajkd.2018.08.013
  9. Portolés J., Gorriz J.L., Rubio E., De Alvaro F., García F., Alvarez-Chivas V., et al. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. // BMC Nephrol. (2013) 14:2. 10.1186/1471-2369-14-2
  10. Evans M., Bower H., Cockburn E., Jacobson Sh., Barany P., Carrero J-J. Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. // Clin Kidney J. (2020) 13:821–7. 10.1093/ckj/sfaa054
  11. Alghali A.G., Li X., Ferguson J.P., Casserly L.F., Cronin C.J., et al.. Quality of care and practice patterns in anaemia management at specialist kidney clinics in Ireland: a national study. // Clin Kidney J. (2018) 11:99–107. 10.1093/ckj/sfx060
  12. KDIGO Anemia Working Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. // Kidney Int. (2012) 2:279–335. 10.1038/kisup.2012.38
  13. Marsch E., Demandt J.A., Theelen T.L., Tullemans B.M., Wouters K., Boon M.R., et al.. Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia. // Eur Heart J. (2016) 37:2993–7
  14. Amdur R.L., Feldman H.I., Gupta J., Yang W., Kanetsky P., Shlipak M., et al.. Inflammation and progression of CKD: the CRIC study. // Clin J Am Soc Nephrol. (2016) 11:1546–56. 10.2215/CJN.13121215
  15. Jankowska E.A., Tkaczyszyn M., Suchocki T., Drozd M., Von Haehling S., Doehner W., et al.. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. // Eur J Heart Fail. (2016) 18:786–95. 10.1002/ejhf.473
  16. Cho M.E., Hansen J.L., Peters C.B., Cheung A.K., Greene T., Sauer B.C. An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease. // Kidney Int. (2019) 96:750–60. 10.1016/j.kint.2019.04.029
  17. Awan A.A., Walther C.P., Richardson P.A., Shah M., Winkelmayer W.C., Navaneethan S.D. Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. // Nephrol Dial Transplant. (2021) 36:129–36. 10.1093/ndt/gfz192

file

download